NCT07057791 2026-04-17
PrE0510
PrECOG, LLC.
Phase 2 Recruiting
Clinical Trials
239 trialsNCT03540420 2026-04-13
ACHILES
Norwegian University of Science and Technology
Phase 2 Active not recruiting
NCT06227546 2026-04-13
MGC018-SCLC
Georgetown University
Phase 2 Active not recruiting
NCT07501169 2026-04-13
STAR-01
Sichuan University
Phase 2 Not yet recruiting
NCT07339059 2026-04-09
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05903092 2026-04-07
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT05957510 2026-04-03
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT05578326 2026-03-30
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06424067 2026-03-30
Phase 2 Study of Fingolimod in Lung Cancers
Medical University of South Carolina
Phase 2 Recruiting
NCT07055581 2026-03-27
Durvalumab as Consolidation for Patients LS-SCLC
Tongji Hospital
Phase 2 Recruiting
NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT04516070 2026-03-05
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT07402343 2026-03-04
T-BRAIN
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT06830694 2026-02-23
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT07423585 2026-02-20
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07149363 2026-02-17
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Recruiting
NCT05419076 2026-02-11
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07398560 2026-02-10
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
The Third Affiliated Hospital of Harbin Medical University
Phase 2 Not yet recruiting
NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
NCT07242547 2026-02-04
MERLIN
Fundación GECP
Phase 2 Recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07373964 2026-01-28
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
China Medical University, China
Phase 2 Recruiting
NCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05450965 2025-12-17
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
Phase 2 Recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06758700 2025-12-05
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT04010357 2025-12-02
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05588388 2025-11-17
BELIEVE
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT04397003 2025-10-22
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT04472949 2025-10-01
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT07200154 2025-09-30
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT07103408 2025-08-05
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07097948 2025-08-01
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT02769832 2025-07-29
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
University of Iowa
Phase 2 Completed
NCT07091305 2025-07-29
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT07076914 2025-07-22
PPI-PROTECT
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Not yet recruiting
NCT03670056 2025-07-20
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
Phase 2 Active not recruiting
NCT07061535 2025-07-11
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting